We are seeking a highly motivated and skilled scientist to join our Technology Unit, the research and development arm of FairJourney Biologics.
Successful candidates may be appointed at Scientist II or Senior Scientist level depending on experience, expertise, and leadership potential.
The Senior Commercialisation Manager is an important position in the Biopharma team of QMI, playing a significant role in initiating and maintaining an effective commercialisation strategy for opportunities principally from the Barts and London School of Medicine and Dentistry.
The post-holder will contribute to the delivery of a range of outputs including technology disclosures, protection of university IP, license and investment transactions, and new venture formation.
Anne Horgan, Partner at Cambridge Innovation Capital, talks about what makes her tick as an investor. She will chair the discussion on Nailing the Fundraise at BioBeat25. Co-organisers, Alisa Molotova, Start-up Mentor, and Miranda Weston-Smith, BioBeat founder chat with her about her role.
With almost 40m UK users, you can’t afford to ignore the power of LinkedIn to reach, connect and engage with other business users.
Join Dan Ince from social media agency BrandWorks Social for a thought-provoking talk on why you need to stand out more than ever on LinkedIn, and practical steps you can take to build visibility without it becoming overwhelming.
Discovery Park is announcing the retirement of Dr. Martino Picardo, esteemed Chairman.
During his seven-year tenure at Discovery Park, Martino’s leadership drove transformative growth, with the Kent science and tech hub recognised as a Life Sciences Opportunity Zone and home to over 180 companies. Over a career spanning more than 30 years, Martino has continually championed the potential of the life sciences sector and the importance of building an environment for innovation to flourish.
by Tony Jones, CEO, One Nucleus
RxCelerate, the Cambridge-based out-sourced drug discovery and development leader, has unveiled a world-class Scientific Advisory Board (SAB) for its rapidly growing antibody discovery group, RxBiologics.
Data presented at AACR Annual Meeting in Chicago
Cambridge, UK – 29 April 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB097 at the American Association for Cancer Research (AACR) annual meeting held in Chicago, April 25-30. MB097 is an LBP in development as a co-therapy for immune checkpoint inhibitors (CPI) such as MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab).
One Nucleus is a dynamic not-for-profit Life Sciences and Healthcare membership organisation headquartered in Cambridge. We support institutions, companies and individuals in the Life Sciences sector. This support helps them achieve, or better still exceed, the goals they have set for themselves. Biomedical and Healthcare R&D has always been impactful in driving social and economic progress.